Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.

Détails

ID Serval
serval:BIB_89BAB19CF382
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.
Périodique
AIDS
Auteur(s)
Yerly S., von Wyl V., Ledergerber B., Böni J., Schüpbach J., Bürgisser P., Klimkait T., Rickenbach M., Kaiser L., Günthard H.F., Perrin L.
ISSN
0269-9370
Statut éditorial
Publié
Date de publication
2007
Volume
21
Numéro
16
Pages
2223-2229
Langue
anglais
Résumé
OBJECTIVES: Representative prevalence data of transmitted drug-resistant HIV-1 are essential to establish accurate guidelines addressing resistance testing and first-line treatments. METHODS: Systematic resistance testing was carried out in individuals in Switzerland with documented HIV-1 seroconversion during 1996-2005 and available samples with RNA > 1000 copies/ml obtained within 1 year of estimated seroconversion. Resistance interpretation used the Stanford list of mutations for surveillance of transmitted drug resistance and the French National Agency for AIDS Research algorithm. RESULTS: Viral sequences from 822 individuals were available. Risk groups were men having sex with men (42%), heterosexual contacts (32%) and intravenous drug users (20%); 30% were infected with non-B subtype viruses. Overall, prevalence of transmitted resistance was 7.7% [95% confidence interval (CI), 5.9-9.5] for any drug, 5.5% (95% CI, 3.9-7.1) for nucleoside reverse transcriptase inhibitors, 1.9% (95% CI, 1.0-2.8) for non-nucleoside reverse transcriptase inhibitors and 2.7% (95% CI, 1.6-3.8) for protease inhibitors. Dual- or triple-class resistance was observed in 2% (95% CI, 0.8-2.5). No significant trend in prevalence of transmitted resistance was observed over years. There were no differences according to ethnicity, risk groups or gender, but prevalence of transmitted resistance was highest among individuals infected with subtype B virus. CONCLUSIONS: The transmission rate of drug-resistant HIV-1 has been stable since 1996, with very rare transmission of dual- or triple-class resistance. These data suggest that transmission of drug resistance in the setting of easy access to antiretroviral treatment can remain stable and be kept at a low level.
Mots-clé
Anti-HIV Agents, Drug Resistance, Viral, Female, Genes, MDR, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Logistic Models, Male, Mutation, Prevalence, Reverse Transcriptase Inhibitors, Risk Factors, Sequence Analysis, DNA, Switzerland
Pubmed
Web of science
Création de la notice
31/03/2009 11:14
Dernière modification de la notice
20/08/2019 14:48
Données d'usage